BRPI1012219C1 - produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina - Google Patents

produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina

Info

Publication number
BRPI1012219C1
BRPI1012219C1 BRPI1012219A BRPI1012219A BRPI1012219C1 BR PI1012219 C1 BRPI1012219 C1 BR PI1012219C1 BR PI1012219 A BRPI1012219 A BR PI1012219A BR PI1012219 A BRPI1012219 A BR PI1012219A BR PI1012219 C1 BRPI1012219 C1 BR PI1012219C1
Authority
BR
Brazil
Prior art keywords
product
treat
environment
biofilm formation
prevent biofilm
Prior art date
Application number
BRPI1012219A
Other languages
English (en)
Portuguese (pt)
Inventor
Charrier Cedric
O' Neil Deborah
Mercer Derry
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of BRPI1012219A2 publication Critical patent/BRPI1012219A2/pt
Publication of BRPI1012219B8 publication Critical patent/BRPI1012219B8/pt
Publication of BRPI1012219C1 publication Critical patent/BRPI1012219C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1012219A 2009-03-31 2010-03-31 produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina BRPI1012219C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16539609P 2009-03-31 2009-03-31
GBGB0905451.1A GB0905451D0 (en) 2009-03-31 2009-03-31 Biofilms
PCT/GB2010/000631 WO2010112848A2 (en) 2009-03-31 2010-03-31 Inhibition of biofilm organisms

Publications (3)

Publication Number Publication Date
BRPI1012219A2 BRPI1012219A2 (pt) 2016-03-29
BRPI1012219B8 BRPI1012219B8 (pt) 2020-05-12
BRPI1012219C1 true BRPI1012219C1 (pt) 2021-05-25

Family

ID=40671951

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012219A BRPI1012219C1 (pt) 2009-03-31 2010-03-31 produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina

Country Status (21)

Country Link
US (3) US9339525B2 (enExample)
EP (1) EP2413949B1 (enExample)
JP (1) JP5727994B2 (enExample)
KR (1) KR101852784B1 (enExample)
CN (2) CN104257645A (enExample)
AU (2) AU2010231136B2 (enExample)
BR (1) BRPI1012219C1 (enExample)
CA (1) CA2755878C (enExample)
CY (1) CY1121175T1 (enExample)
GB (1) GB0905451D0 (enExample)
IL (1) IL215369B2 (enExample)
MX (1) MX358018B (enExample)
NZ (1) NZ595037A (enExample)
PL (1) PL2413949T3 (enExample)
RU (1) RU2548786C2 (enExample)
SG (2) SG10201400926VA (enExample)
SI (1) SI2413949T1 (enExample)
TR (1) TR201821161T4 (enExample)
UA (1) UA106743C2 (enExample)
WO (1) WO2010112848A2 (enExample)
ZA (1) ZA201107140B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
TWI403330B (zh) * 2010-03-29 2013-08-01 Rise technology co ltd 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
GB201016733D0 (en) * 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
WO2012155027A1 (en) 2011-05-12 2012-11-15 Healthpoint, Ltd. Wound debridement compositions containing seaprose and methods of wound treatment using same
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
WO2013076666A1 (en) * 2011-11-23 2013-05-30 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
MX344635B (es) * 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
WO2014016979A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物活性調節剤及び微生物の活性を調節する方法
CA2922516A1 (en) * 2013-08-27 2015-03-19 The University Of British Columbia Small cationic anti-biofilm and idr peptides
GB201405891D0 (en) * 2014-04-02 2014-05-14 Novabiotics Ltd Modified antimicrobial peptides
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
WO2017134661A1 (en) * 2016-02-04 2017-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
DK3416669T3 (da) * 2016-02-19 2025-08-18 Klaus Brandenburg Midler og metoder til behandling af bakterielle infektioner
WO2017176796A1 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
EP3241570A1 (en) * 2016-05-02 2017-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide and hyaluronic acid coatings
AU2017264967B2 (en) * 2016-05-12 2024-07-25 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting biofilm deposition and production
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
WO2018020435A1 (en) 2016-07-27 2018-02-01 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
EA201991331A1 (ru) 2016-12-15 2019-11-29 N-ацетилцистеин для применения в качестве антибактериального агента
AU2017381394A1 (en) * 2016-12-22 2019-07-25 The University Of Sydney Biofilm disrupting composition
JP7138110B2 (ja) * 2017-01-05 2022-09-15 コーメディクス・インコーポレーテッド 成熟バイオフィルムに対して有効な、抗菌ヒドロゲルを含む抗菌組成物
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
CN110740744A (zh) 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用
RU2664708C1 (ru) * 2017-06-08 2018-08-21 Сергей Иванович Черныш Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых
CN108048359B (zh) * 2017-12-27 2020-12-01 广州立白企业集团有限公司 一种牙菌斑生物膜模型的培养方法和优化的生物膜活菌计数法及应用
US20220249599A1 (en) * 2018-03-13 2022-08-11 Peptilogics, Inc. Treatment of implants with engineered antimicrobial amphiphilic peptides
CN108753632A (zh) * 2018-05-25 2018-11-06 安徽中医药大学 一种溶解白念珠菌生物被膜胞外基质的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3866775B1 (en) * 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
CA3132400C (en) 2019-03-18 2026-05-12 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
CN110402928A (zh) * 2019-08-08 2019-11-05 杭州博菲医疗器械有限公司 一种抑菌功能液及应用该抑菌功能液的导管组件
CN110583697B (zh) * 2019-09-20 2021-04-06 浙江工商大学 去除铜绿假单胞菌生物膜用的高效化学生物制剂及其应用
CN111675751B (zh) * 2020-04-08 2022-06-14 天津医科大学口腔医院 一种抗菌肽及其应用
GB202010268D0 (en) * 2020-07-03 2020-08-19 Novabiotics Ltd Nail formulations and treatment regimes
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
US6475434B1 (en) * 1998-12-07 2002-11-05 Baylor College Of Medicine Composition and methods for preventing and removing biofilm embedded microorganisms from the surface of medical devices
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
DK1927597T3 (en) * 2004-08-18 2017-02-13 Novabiotics Ltd ANTIBACTERIAL PEPTIDES
WO2007050565A2 (en) * 2005-10-25 2007-05-03 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
ZA200805191B (en) * 2005-11-28 2009-08-26 Hk Omega Biopharma Ltd Materials and methods for treating viral infections with a cysteamine compound
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20100151042A1 (en) * 2007-05-25 2010-06-17 Hao Yi Liang Materials and Methods for Treating Influenza Infections
US20090209650A1 (en) * 2008-02-17 2009-08-20 Francis Chi Materials and Methods for Improving the health of Shrimp
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US20160106689A1 (en) * 2014-09-22 2016-04-21 Novabiotics Limited Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds

Also Published As

Publication number Publication date
US20190175528A1 (en) 2019-06-13
CN102387794A (zh) 2012-03-21
CA2755878C (en) 2018-04-24
TR201821161T4 (tr) 2019-01-21
JP2012522037A (ja) 2012-09-20
AU2016210742B2 (en) 2017-08-10
WO2010112848A3 (en) 2011-01-27
US20160206575A1 (en) 2016-07-21
SI2413949T1 (sl) 2019-02-28
IL215369B2 (en) 2023-02-01
JP5727994B2 (ja) 2015-06-03
CY1121175T1 (el) 2020-05-29
BRPI1012219A2 (pt) 2016-03-29
CA2755878A1 (en) 2010-10-07
AU2010231136B2 (en) 2016-08-04
PL2413949T3 (pl) 2019-04-30
WO2010112848A2 (en) 2010-10-07
CN102387794B (zh) 2015-11-25
IL215369A (en) 2013-02-03
US9339525B2 (en) 2016-05-17
AU2016210742A1 (en) 2016-08-25
EP2413949B1 (en) 2018-10-10
US20120189682A1 (en) 2012-07-26
ZA201107140B (en) 2012-06-27
NZ595037A (en) 2013-07-26
CN104257645A (zh) 2015-01-07
KR20120003893A (ko) 2012-01-11
UA106743C2 (uk) 2014-10-10
KR101852784B1 (ko) 2018-04-30
AU2010231136A1 (en) 2011-09-29
MX2011010258A (es) 2011-10-19
EP2413949A2 (en) 2012-02-08
IL215369B (en) 2022-10-01
SG10201400926VA (en) 2014-10-30
SG174278A1 (en) 2011-10-28
MX358018B (es) 2018-08-02
BRPI1012219B8 (pt) 2020-05-12
GB0905451D0 (en) 2009-05-13
RU2548786C2 (ru) 2015-04-20

Similar Documents

Publication Publication Date Title
BRPI1012219B8 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BR112015028385A2 (pt) composição compreendendo bactérias de ácido láctico para uso no tratamento preventivo e/ou curativo da vaginose bacteriana
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
UY36422A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
BR112017006526A2 (pt) composição e kits para inibição de infecção microbiana patogênica e métodos de usar os mesmos
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BR112013005426A2 (pt) &#34;composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação.&#34;
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
BR112012006010A2 (pt) composto de glicina
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
CO2022000270A2 (es) Inhibidores de enzimas
BRPI0916885B8 (pt) composição farmacêutica
BR112017020796A2 (pt) compostos, composição farmacêutica e kit
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112019008411A2 (pt) materiais e métodos para o controle de biofilme
BR112015032284A2 (pt) dispositivo médico compreendendo colágeno-vi

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2573 DE 28/04/2020 QUANTO AO TITULO E A PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF